Taltz Safety, Efficacy Stay Robust in Spondyloarthritis at 3 Years

(MedPage Today) -- Short-term improvements in axial spondyloarthritis (axSpA) symptoms seen with the interleukin-17A blocker ixekizumab (Taltz) persisted and even increased further among clinical trial participants who continued on the drug for...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news